- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
India Gains 2 Adalimumab Biosimilars in 1 Week as United States, Europe Await Market Entry
Mumbai-based Glenmark Pharmaceuticals launched a biosimilar adalimumb, Adaly, in the Indian marketplace this week, following Hetero's launch of Mabura.
Mumbai-based Glenmark Pharmaceuticals launched a biosimilar adalimumb (Humira) in the Indian marketplace this week, reports The Economic Times. The drug, which will be marketed as Adaly, has launched at an undisclosed price discount to the reference product, and will be commercialized under an agreement with Cadila Healthcare.
"The launch of Adaly reaffirms our commitment toward meeting unmet needs of patients and providing the latest treatment options,” Sujesh Vasudevan of Glenmark told the Times.
News of Adaly’s launch follows close on the heels of another biosimilar adlaimumab’s Indian market entry: on January 3, drug maker Hetero launched its own biosimilar drug under the brand name Mabura. Both new biosimilars enter a marketplace in which drug maker Zydus has already launched a biosimilar adalimumab, under the brand name Exemptia, which came on the market in 2014 as the world’s first commercially available biosimilar adalimumab product.
While the Indian marketplace will now have additional, cost-saving options available, patients in other areas of the world face a longer wait for biosimilar adalimumab. In September 2017, drug maker Amgen announced that it had reached a settlement with Humira’s sponsor, AbbVie, after a lengthy patent dispute. The settlement, the terms of which were not disclosed, cleared Amgen to launch its biosimilar—Amjevita—in the United States in 2023 (despite the drug having been approved by the FDA in September 2016). Amgen fared slightly better in the European Union, where it will be allowed to introduce the drug in October of this year.
As the European and US markets await biosimilar availability, AbbVie has raised prices on the innovator Humira by 9.7% for 2018, an increase that is estimated to cost the US healthcare system an additional $1.2 billion this year alone. In 2016, Humira garnered $16.08 billion in global sales—up 14.7% from the previous year—making the reference adalimumab the top-earning drug worldwide.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
